drugset
drugset / Trial / NCT05647447

Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate

NCT05647447 ↗

Phase 0 Withdrawn University of Kansas Medical Center
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the preliminary efficacy of in reducing the frequency and severity of hot flashes in men on androgen deprivation therapy (ADT).

Timeline

Start
2023-01-03
Primary completion
2023-09-22
Completion
2023-10-05

Outcome

Outcome not reported

Stopped: “Development of the drug program has been discontinued”

Drugs

EvaluationDrugModalityDoseRoute
Subject Osanetant Small molecule 200 mg Oral

Indications

prostate adenocarcinoma